ArticleInternational journal of clinical pharmacy2025

Real-world safety assessment of ublituximab: a pharmacovigilance analysis based on the FDA adverse event reporting system.

Sen Luo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.